Mylan Buspirone Launch Awaits Bristol Appeal Of BuSpar Patent Order
Executive Summary
Bristol-Myers Squibb appears to have at least two more chances to block a generic version of BuSpar from coming to market following a March 13 preliminary injunction imposed by Judge Ricardo Urbina in Washington, D.C. federal court.
You may also be interested in...
BuSpar Antitrust Suit Will Test Theory Of “Orange Book” Abuse
A multi-state antitrust suit against Bristol-Myers Squibb over the BuSpar patent challenge will test the theory that some manufacturers are abusing the "Orange Book" patent listing process
BuSpar Antitrust Suit Will Test Theory Of “Orange Book” Abuse
A multi-state antitrust suit against Bristol-Myers Squibb over the BuSpar patent challenge will test the theory that some manufacturers are abusing the "Orange Book" patent listing process
BuSpar Appeal: Bristol Argues Mylan Evaded Waxman/Hatch By Filing Suit
Mylan attempted to circumvent Waxman/Hatch procedures by filing suit against Bristol-Myers Squibb over its BuSpar (buspirone) metabolite patent before issuing a Paragraph IV certification, Bristol argued before the federal circuit appeals court in Washington D.C. July 12.